“Results of a phase 3 trial in the New England Journal of Medicine show 80% protection for the single-dose tetravalent (four-strain) Butantan-Dengue Vaccine among participants with no evidence of previous dengue exposure and 89% protection in those with a history of exposure.
The vaccine is the culmination of years of research from Brazil’s Butantan Institute, and the study included results from 16 Brazilian centers located in all five regions of the country.”
From CIDRAP.
“In a historic move, the government of Mali has introduced the human papillomavirus (HPV) vaccine into its routine immunisation programme. During a ceremony held in Bamako earlier this month, and attended by numerous dignitaries and international partners, Gavi and the Ministry of Health and Social Development emphasised the importance of this initiative, terming it a significant step forward in preventing cervical cancer among Malian women.”
From Gavi.
“Measles vaccination has saved 94 million lives globally since 1974. Of those, 92 million were children.”
From Our World in Data.
“Between October 3 and 6, 2024, more than 6.5 million children were vaccinated in a successful synchronized polio campaign between Kenya and Uganda. This cross-border achievement began with a coordinated launch in Bungoma District, Kenya, and Mbale District, Uganda.
Both countries have set an exemplary standard in their recent synchronized polio vaccination campaign conducted this week, which focused on high-risk cross-border regions. By conducting these campaigns on the same dates, sharing real-time information, both countries ensured that children under five in these vulnerable areas were reached effectively, reducing the chance of cross-border virus transmission.”
“Doctors have begun trialling the world’s first mRNA vaccine against the vomiting bug norovirus in the hope the jab could bring huge health and economic benefits.
Norovirus causes sickness and diarrhoea and can spread very rapidly between people who are in close contact, with outbreaks often occurring in hospitals, care homes, schools and nurseries.
While most people recover within two to three days, the virus can be serious, particularly for the very young, elderly or people with a weakened immune system…
Called Nova 301, the phase 3 clinical trial is to run for two years, and will enrol 25,000 adults – with a focus on those over the age of 60 – from countries including Japan, Canada and Australia.”
From The Guardian.
